Brief: Molecure (Wse Moc) And Nasdaq-Listed Biotechnology Company Ocean Biomedical (Nasdaq Ocea) Sign An Exclusive Licensing Agreement For The Development And Commercialization Of Selective Ykl-40 Inhibitors
15/10/2024 13:10
Oct 15 (Reuters) - Molecure SA MOCP.WA :
* MOLECURE (WSE: MOC) AND NASDAQ-LISTED BIOTECHNOLOGY
COMPANY
OCEAN BIOMEDICAL (NASDAQ: OCEA) SIGN AN EXCLUSIVE LICENSING
AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF SELECTIVE
YKL-40 INHIBITORS.
Source text for Eikon: ID:nGNX5tXYzh
Further company coverage: MOCP.WA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Molecure SA
See all newsBrief: Molecure Q1 Net Loss 4.1 Mln Zlotys
Brief: Molecure Says Its In-Consortium Project Selected For Funding By Medical Research Agency
Brief: Molecure To Sell 4.12 Mln Series K Shares and 2.0 Mln Existing Shares At 5 Zlotys/Shr
Brief: Molecure Starts ABB For Up to 4.12 Mln New Series K Shares And Up To 2.0 Mln Existing Shares
Brief: Molecure Signs Conditional Investment Agreement With MS Galleon And Szumowski Investments